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1. Introduction
1.1 Structural bioinformatics contributions in -omics studies
The Acceleration of COVID-19 research in Proteomics and Transcriptomics 
studies occurred swiftly due to the massive amount of investment and advances 
in biomanufacturing [1, 2]. Moreover, the repurposing drug research has elicited 
remdesivir as the FDA-approved drug for COVID-19, despite mixed result from the 
WHO solidarity trial [3]. More drug leads are also currently undergoing clinical 
trial as well. This rapid development in the rational drug design is strongly associ-
ated with the field of structural bioinformatics. As for now (Early December 2020), 
there are more than 600 deposited SARS-CoV-2 Protein structures in the PDB (per 
December 2020, in the http://www.rcsb.org). They are SARS-CoV-2 Proteins with 
various conformations, and bindings with various ligands [4]. Hence, those proteins 
structures and their annotated functions are currently subject of the extensive 
COVID-19 drug development along with hefty investment from the pharmaceutical 
companies. However, in the other side of the story, non-protein biomolecular struc-
tures are currently still off the radar. There are only handful of initiatives for the 
COVID-19 transcriptomics-based drugs [5–7]. However, drug-based transcriptomics 
initiatives in canceromics are more mature. Breast cancer transcriptomics-based 
leads are currently under development [8–10]. That particular progress could be elic-
ited due to the application of structural bioinformatics method for prediction the 2D 
and 3D model of the nucleic acids [11]. However, massive clinical applications still 
in favors for the proteomics-based drugs due to the stability of the bioassay experi-
ments. In the area of natural products computation, the only realistic approach is 
still the proteomics-based one. For instance, propolis, as a resinous material from 
bees, was a subject of intensive molecular simulation research for its respective 
compounds constituency as diabetes drug candidates [12]. Hence, the same mate-
rial also employed for the possibility as COVID-19 leads compound [13]. Moreover, 
various secondary metabolite sources were also investigated as drug candidates with 
the molecular simulation research, such as ayurvedic plants of India, and various 
sources of Chinese herbal medicine [14–18]. In this regard, bioinformaticians should 
proceed with mindful and prudent manner on the deployment of the molecular 
docking method as there are validation issues that should be resolved before working 
on the samples [19, 20]. That includes the utilization of the docking decoys, reitera-
tions of Tc-PLIF value, cross-docking, redocking of the attached ligand, and the 
refinement of the RMSD parameter [21–25]. However, the easiest validation method 
is the ligand redocking, provided the structure is exist in the PDB repository. The 
decoy deployment is the most computationally extensive of all, albeit of its high 
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accuracy [26]. In this end, the measurement of the computational cost should be 
taken into consideration when applying molecular simulation is needed [27].
2. Pharmacogenomics and personalized medicine
Although it is still in its infancy, currently there is research that investigates 
the tendency that certain population group will be more vulnerable to COVID-
19. For instance, Population with gene pool of Neanderthals was predicted to be 
vulnerable considerably [28]. In Indonesia, pharmacogenomics study has elicited 
correlation between anti-tuberculosis drug-induced liver injury (AT-DILI) sever-
ity and NAT2 phenotypes [29]. Moreover, expression of Long non-coding RNA 
(lncRNA) in diabetic patient is a useful lead for the progression of the epigenetic 
repertoire in the human cell [30]. Then, Molecular genomic is playing important 
role to annotate the cardiac function analysis [31]. The 7-day regiment deploy-
ment of the malaria drug primaquine is tolerated for patient with normal level of 
glucose-6-phosphate dehydrogenase (G6PD). Moreover, the resistance tendency 
of certain population group against malaria parasite has been observed as well 
[32]. Cancer is one of the most extensively studied disease in the pharmacoge-
nomics field, in the light of the intensive computational biology tools, as tenden-
cies for prevalence were elucidated in different races [33, 34]. Thus, the progress 
of epigenetics research has leveraged the pharmacogenomics field with various 
findings of biomarkers for cancer [35]. The various progresses in the pharmacoge-
nomics field have shown that the molecular mechanism of diseases is beginning to 
be uncovered accordingly, especially with the development of epigenetics marker 
database [36]. Bioinformatics also play important role in annotating pharmacoge-
nomics data, especially for the development of the genomics database and the 
disease-outcome prediction methods [37].
3. Metabolomics and disease biomarkers
The forefront of the metabolomics research is mainly the standard instru-
ment in the analytical biochemistry such as HPLC and GC–MS, and also some 
supporting organic chemistry instrumentation such as C-NMR, H-NMR, UV, 
and IR [28–30, 38–40]. However, the deployment of the data science approach in 
interpretation of the metabolomics data enables the analysis of the large data sets, 
and eventually the data annotation in the biological database [41, 42]. Natural 
products research is one of the most dynamic fronts in the metabolomics research. 
Herbal medicine clinical trial toward COVID-19 patients show acceptable result 
for patients with mild symptoms, provided that the standard therapy still apply 
[43–45]. Moreover, secondary metabolite could serve as disease biomarkers. 
Insulin-resistant individuals will have decreased serum level of glycine, and also 
poor biotin metabolism [46]. Currently, probiotic metabolites are undergone exten-
sive research to determine their possible anti-SARS-CoV-2 properties [47]. Propolis 
studies are also focused on the metabolomics side in order to provide sufficient data 
to the structural bioinformatics research, especially to determine the inhibitory 
activities against the SARS-CoV-2 virus [48–51]. Up to today, there are still limited 
number of the approved natural product based drugs, such as aspirin, penicillin, 
and taxol [52]. Bioinformatics research has been optimized to develop a more 
comprehensive biological conclusion in natural product chemistry, such as the 
annotation of naringin role in cancer, bioactive compounds of Zingeber officinale, 
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and caffeine-aspirin interaction [53–55]. So more efforts should be elicited to 
improve the completeness of the natural products library, mainly to supplement the 
standard chemical compounds library such as Pubchem, and drug database such as 
drugbank. Hence, biomarkers could be elicited not only as small organic molecules, 
but also as larger biomolecules. For instance, the insulin level is one of the indicator 
of the diabetes progression, and indicator for the therapeutic options available [56]. 
Diabetic biomarker could be manifested as non-coding RNA as well [57, 58].
4. Medicinal chemistry and drug design in omics study
The metabolomics study is definitely inseparable from medicinal chemistry due 
to their overlapping domain [59]. The development of the metabolomics library 
enables the construction of the rich chemical-structures library, as well as their 
respective functional groups from the natural products [57–62]. Custom-made 
library will supplement the existing libraries, such as the pubchem, drugbank, and 
KEGG database [63–65]. In this regard, the availability of the functional-groups 
library will support the fragment-based drug design, where specialized algorithm 
was devised to inhibit every corner of the protein’s cavity [66, 67]. Hence, the 
main challenge of this approach will be in the medicinal chemistry perspective, 
when extrapolating the in silico research into the in vitro one become neces-
sary. Synthesizing custom-made compounds from fragment library will not be 
straightforward due to the special reaction condition needed, the existence of the 
new structural backbone, and the availability of the chemical regents [68]. In this 
end, the current standing of the medicinal chemistry field is still depend upon the 
derivatization of the current structural library of compounds, in order to develop 
new lead with feasible reaction conditions [69]. Metabolomics plays dominant role 
in developing such library. One of the application of this particular approach is the 
development of ceftaroline, which is a fifth-generation broad-spectrum cephalo-
sporin antibiotic [70].
5. Outlook
Parallelization in the Drug Biomanufacturing with incremental optimiza-
tion will facilitate the pipeline of therapeutic agent development [71, 72]. Such 
biomanufacturing efforts will be enhanced with the implementation of Artificial 
Intelligence (AI) for massive drug screening that could be beneficial for multi-
components drug lead such as herbal medication, and machine-learning based 
implementation for such pipelines has been devised accordingly in COVID-19 leads 
development [73–76]. The extensive utilization of the common data science meth-
ods in bioinformatics, such as machine learning, will eventually provide insight that 
the management of life sciences data requires more than just becoming application 
users [77]. Massive automation efforts in the field of life sciences will eventually 
push forward with the inevitable integration with formal sciences, namely with 
both computer science and data science [78]. In this end, Bioinformatics will play 
important role to manage the experimental data from the life sciences lab [79]. 
For instance, utilization of the SUPERFAMILY and Gene Ontology database for 
annotating the protein domain expression of the Plasmodium sp. parasite could be 
a doable venue [80, 81]. Thus, the promises that already delivered by the omics 
studies will eventually shed light to the current state of the COVID-19 pandemic 
(per December 2020), and could elicit various therapeutic options for many more 
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infectious diseases. However, non-communicable disease such as various types of 
cancer and diabetes will remain a challenging task to resolve as they invoke deep 
understanding of the human immunological system. It involves the utilization of 
the immunoinformatics tools that proceed beyond this chapter [82, 83]. Hence, it 
should be reminded that the basic sciences behind the omics studies could not be 
overlooked. Medicinal chemistry, biochemistry, molecular biology, biomedicine 
and biotechnology will remain important, as well as emerging sciences such as 
bioinformatics and data sciences.
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